Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025Open Access

HCG22 as a Non-Invasive Saliva-Based lncRNA Diagnostic Marker for Oral Cancer: Evidence from an Indian Clinical Study

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPandikannan KrishnamoorthyARAthira S. RajSSSalendra Singh

Discussion

Loading...

Member takes

Overview

Clinical validation of lncRNA HCG22 as a non-invasive diagnostic marker for OSCC, suggesting its potential in early detection.

Key Points

  • HCG22 is a non-invasive lncRNA that shows potential as a diagnostic marker for OSCC.
  • In saliva samples, HCG22 demonstrated high diagnostic performance with an AUROC of 0.76, facilitating detection.
  • Clinical validation involved robust lncRNA analysis and RT-PCR in an Indian OSCC cohort, establishing relevance.
  • Lower levels of HCG22 are linked to advanced OSCC stages and poorer survival outcomes in patients.

Cite This Study

Krishnamoorthy et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf560https://doi.org/10.1101/2025.07.30.25332447
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of Potential Salivary Biomarkers and Enriched Protein Domain/Motif Families for Early Detection and Lymph Node Invasion in OSCC Patients of the Indian Population2025
  2. 2Salivary Exosomal MicroRNAs as Non-Invasive Biomarkers for Early Detection of Oral Squamous Cell Carcinoma: A Prospective Diagnostic Study2025
  3. 3Identification of a Novel Salivary Four-miRNA Signature for Non-Invasive Diagnosis of Oral Squamous Cell Carcinoma2025
  4. 4Identification of Non-Invasive Diagnostic Markers for Oral Squamous Cell Carcinoma Through Salivary Microbiome and Gene Expression Analysis2025
  5. 5Application of a Saliva‐Based Liquid Biopsy for the Detection of <scp>HPV</scp> in Patients With Oral Cavity Squamous Cell Carcinoma (<scp>OCSCC</scp>)2025